9-Jan-2026 5:00 AM CST - Business Wire Insuletto AnnounceFourthQuarterand Full Year2025Financial Results onFebruary 18, 2026 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on
2-Jan-2026 8:18 AM CST - Investing Snacks Insulet Stake Reduction: Fund Sells 38.6% of Shares Despite an Insulet stake reduction by a major fund, analysts maintain a 'Moderate Buy' rating. Discover why institutional selling contrasts with strong earnings and a bullish price target.
2-Jan-2026 6:34 AM CST - Yahoo Finance Singapore Is it the Right Time to Add Insulet Stock to Your Portfolio? PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
22-Dec-2025 8:07 AM CST - Yahoo Finance Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm's price target on Insulet to $390 from $412 with a Buy rating on the shares.
16-Dec-2025 12:49 PM CST - Yahoo Finance Is Insulet Stock Underperforming the Nasdaq? Although Insulet has underperformed the Nasdaq recently, analysts remain highly optimistic about the stock's prospects.
16-Dec-2025 6:00 AM CST - Business Wire Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation:
15-Dec-2025 12:40 PM CST - Yahoo Finance Assessing Insulet (PODD) Valuation After Recent Share Price Pullback Insulet (PODD) has been quietly recalibrating after a choppy past month, with the stock down around 11% even as its year to date gain sits in the mid teens, inviting a closer look. See our latest analysis for Insulet.
11-Dec-2025 1:00 PM CST - Benzinga A Look Into Insulet Inc's Price Over Earnings In the current market session, Insulet Inc. (NASDAQ: PODD) share price is at $296.82, after a 0.55% spike. Moreover, over the past month, the stock fell by 11.16%, but in the past year, went up by 9.73%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session.
9-Jan-2026 5:00 AM CST - Business Wire Insuletto AnnounceFourthQuarterand Full Year2025Financial Results onFebruary 18, 2026 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on
2-Jan-2026 8:18 AM CST - Investing Snacks Insulet Stake Reduction: Fund Sells 38.6% of Shares Despite an Insulet stake reduction by a major fund, analysts maintain a 'Moderate Buy' rating. Discover why institutional selling contrasts with strong earnings and a bullish price target.
2-Jan-2026 6:34 AM CST - Yahoo Finance Singapore Is it the Right Time to Add Insulet Stock to Your Portfolio? PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.
22-Dec-2025 8:07 AM CST - Yahoo Finance Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm's price target on Insulet to $390 from $412 with a Buy rating on the shares.
16-Dec-2025 12:49 PM CST - Yahoo Finance Is Insulet Stock Underperforming the Nasdaq? Although Insulet has underperformed the Nasdaq recently, analysts remain highly optimistic about the stock's prospects.
16-Dec-2025 6:00 AM CST - Business Wire Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation:
15-Dec-2025 12:40 PM CST - Yahoo Finance Assessing Insulet (PODD) Valuation After Recent Share Price Pullback Insulet (PODD) has been quietly recalibrating after a choppy past month, with the stock down around 11% even as its year to date gain sits in the mid teens, inviting a closer look. See our latest analysis for Insulet.
11-Dec-2025 1:00 PM CST - Benzinga A Look Into Insulet Inc's Price Over Earnings In the current market session, Insulet Inc. (NASDAQ: PODD) share price is at $296.82, after a 0.55% spike. Moreover, over the past month, the stock fell by 11.16%, but in the past year, went up by 9.73%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session.
